David Katz, Founder & CSO, and Robert Jacks, President and CEO, Sparrow Pharmaceuticals – Pioneering Relief: A prescription for changing lives and healthcare
Episode 79 of the Welcome to the Arena from ICR – Conversations with Today's Innovators & Business Leaders podcast, hosted by ICR, titled "David Katz, Founder & CSO, and Robert Jacks, President and CEO, Sparrow Pharmaceuticals – Pioneering Relief: A prescription for changing lives and healthcare" was published on June 14, 2023 and runs 29 minutes.
June 14, 2023 ·29m · Welcome to the Arena from ICR – Conversations with Today's Innovators & Business Leaders
Summary
Sometimes abstract thinking that can lead to real breakthroughs. The knowledge and innovative thinking of today's guests led to an life-changing solution to an ongoing 75-year puzzle. Today we sit down with David Katz and Robert Jacks; Chief Scientific Officer, and President & CEO, of Sparrow Pharmaceuticals, respectively. Sparrow has come up with a groundbreaking way to help patients who need steroid treatments. Robert was previously President & CEO of Indalo Therapeutics, a clinical-stage biotech company developing therapeutics for serious fibrotic diseases, and President, CFO, and Co-Founder of Symbiomix Therapeutics, which was sold after achieving NDA approval for Solosec®. Robert began his career in finance and product development at Pfizer, where he last worked as the Director of Business Development for Oncology and Infectious Diseases.Prior to Sparrow, David Katz was a pharmaceutical R&D leader at Abbott and AbbVie, where he led clinical development and drug discovery teams, and was a personalized medicine pioneer. David is dedicated to the mentorship of the next generation of life sciences entrepreneurs, currently as an entrepreneur-in-residence at Oregon Health & Science University. He has published over 50 peer-reviewed scientific papers.Highlights:David explains Sparrow's key focus, and they problem they are solving (2:49)How Sparrow planned for the economics of developing a new treatment (5:13)Robert explains why he jumped on board at Sparrow (7:21)David talks about his background, mentors, and interests in the field (8:36)David explains the 75-year puzzle of glucocorticoids (13:50)How Sparrow's SPI-62 treatment can change a patient's life, and how it's a novel approach (16:27)Sparrow’s current clinical trials (19:41)Sparrow's strategic partners (21:20)Why an investor would be attracted to Sparrow now (22:19)Managing being on 2 different coasts, and how they attract talent (23:18)The businesses/leaders that David admires (24:40)David talks about his passion for both art and science (25:58)Robert discusses Sparrow's unique value proposition (26:51)Links:ICR TwitterICR LinkedInICR WebsiteRobert Jacks on LinkedInDavid Katz on LinkedInSparrow Pharmaceuticals on LinkedInSparrow Pharmaceuticals WebsiteFeedback:If you have questions about the show, or have a topic in mind you'd like discussed in future episodes, email our producer, [email protected].
Episode Description
Sometimes abstract thinking that can lead to real breakthroughs. The knowledge and innovative thinking of today's guests led to an life-changing solution to an ongoing 75-year puzzle. Today we sit down with David Katz and Robert Jacks; Chief Scientific Officer, and President & CEO, of Sparrow Pharmaceuticals, respectively. Sparrow has come up with a groundbreaking way to help patients who need steroid treatments.
Robert was previously President & CEO of Indalo Therapeutics, a clinical-stage biotech company developing therapeutics for serious fibrotic diseases, and President, CFO, and Co-Founder of Symbiomix Therapeutics, which was sold after achieving NDA approval for Solosec®. Robert began his career in finance and product development at Pfizer, where he last worked as the Director of Business Development for Oncology and Infectious Diseases.
Prior to Sparrow, David Katz was a pharmaceutical R&D leader at Abbott and AbbVie, where he led clinical development and drug discovery teams, and was a personalized medicine pioneer. David is dedicated to the mentorship of the next generation of life sciences entrepreneurs, currently as an entrepreneur-in-residence at Oregon Health & Science University. He has published over 50 peer-reviewed scientific papers.
Highlights:
- David explains Sparrow's key focus, and they problem they are solving (2:49)
- How Sparrow planned for the economics of developing a new treatment (5:13)
- Robert explains why he jumped on board at Sparrow (7:21)
- David talks about his background, mentors, and interests in the field (8:36)
- David explains the 75-year puzzle of glucocorticoids (13:50)
- How Sparrow's SPI-62 treatment can change a patient's life, and how it's a novel approach (16:27)
- Sparrow’s current clinical trials (19:41)
- Sparrow's strategic partners (21:20)
- Why an investor would be attracted to Sparrow now (22:19)
- Managing being on 2 different coasts, and how they attract talent (23:18)
- The businesses/leaders that David admires (24:40)
- David talks about his passion for both art and science (25:58)
- Robert discusses Sparrow's unique value proposition (26:51)
Links:
Sparrow Pharmaceuticals on LinkedIn
Sparrow Pharmaceuticals Website
Feedback:
If you have questions about the show, or have a topic in mind you'd like discussed in future episodes, email our producer, [email protected].
Similar Episodes
Apr 8, 2026 ·8m
Apr 1, 2026 ·18m
Mar 25, 2026 ·14m
Mar 18, 2026 ·24m
Mar 11, 2026 ·37m
Mar 4, 2026 ·13m